Strong Price Momentum and Market Outperformance
On 24 Nov 2025, Venus Remedies touched an intraday high of Rs.728, representing a 3.62% rise during the trading session. The stock outperformed its sector by 1.47% and has recorded gains for four consecutive days, delivering a cumulative return of 28.3% over this period. This upward trajectory has positioned Venus Remedies well above its key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained buying interest and positive price action.
The broader market context also supports this performance. The Sensex opened 88.12 points higher and was trading at 85,455.79, just 0.4% shy of its own 52-week high of 85,801.70. The benchmark index has been on a three-week consecutive rise, gaining 2.69%, with mega-cap stocks leading the charge. Venus Remedies’ rally aligns with this bullish market environment, further reinforcing its strong position within the Pharmaceuticals & Biotechnology sector.
Our latest monthly pick, this Large Cap from Aluminium & Aluminium Products, is outperforming the market! See the analysis that helped our Investment Committee select this winner.
- - Market-beating performance
- - Committee-backed winner
- - Aluminium & Aluminium Products standout
Financial Performance Underpinning the Rally
Venus Remedies’ financial metrics provide a clear foundation for the recent price strength. The company’s net profit for the quarter stood at Rs.20.13 crores, reflecting a growth of 473.5% compared to previous periods. This substantial increase in profitability has been consistent, with positive results declared for four consecutive quarters. The half-yearly return on capital employed (ROCE) reached a high of 13.99%, indicating efficient utilisation of capital resources.
Inventory turnover ratio for the half-year was recorded at 6.58 times, the highest in recent periods, suggesting effective inventory management and operational efficiency. Additionally, the return on equity (ROE) stands at 10.5%, complemented by a price-to-book value of 1.6, which points to an attractive valuation relative to peers and historical averages.
Over the past year, Venus Remedies has delivered a total return of 142.67%, significantly outpacing the Sensex’s 8.02% return during the same timeframe. Profit growth over the year has been recorded at 183%, highlighting the company’s strong earnings momentum. The stock’s PEG ratio of 0.1 further illustrates the relationship between its price and earnings growth, underscoring the market’s recognition of its financial trajectory.
Market Capitalisation and Debt Profile
Venus Remedies maintains a low debt-to-equity ratio, averaging zero, which reflects a conservative capital structure and limited reliance on external borrowings. This financial prudence supports the company’s ability to sustain growth and manage risks effectively. The market capitalisation grade of 4 indicates a moderate size within its sector, yet the stock’s performance has been notable both in the short and long term.
Venus Remedies caught your attention? Explore our comprehensive research report with in-depth analysis of this micro-cap Pharmaceuticals & Biotechnology stock – fundamentals, valuations, financials, and technical outlook!
- - Comprehensive research report
- - In-depth micro-cap analysis
- - Valuation assessment included
Historical Price Range and Comparative Performance
The stock’s 52-week low was Rs.272.20, illustrating a substantial price appreciation to the current high of Rs.728. This wide range highlights the significant value creation for shareholders over the past year. Venus Remedies has also outperformed the BSE500 index over the last three years, one year, and three months, demonstrating consistent market-beating returns.
Despite the company’s size and performance, domestic mutual funds hold no stake in Venus Remedies. This absence may reflect a cautious stance or differing research perspectives within the mutual fund community, though it does not detract from the company’s recent financial and market achievements.
Sector and Market Context
Operating within the Pharmaceuticals & Biotechnology sector, Venus Remedies benefits from a dynamic industry environment characterised by innovation and growing demand. The sector itself has shown resilience and growth, with Venus Remedies standing out due to its recent financial results and price performance. The stock’s ability to trade above all major moving averages further signals strong technical momentum relative to its peers.
Summary of Key Metrics
To summarise, Venus Remedies’ key financial and market indicators include:
- New 52-week high price of Rs.728
- Four consecutive days of gains with a 28.3% return in this period
- Net profit growth of 473.5% in the latest quarter
- Half-yearly ROCE at 13.99% and inventory turnover ratio at 6.58 times
- Return on equity of 10.5% and price-to-book value of 1.6
- One-year total return of 142.67% versus Sensex’s 8.02%
- Debt-to-equity ratio averaging zero, indicating a debt-free position
These figures collectively illustrate the factors contributing to Venus Remedies’ recent milestone and sustained market momentum.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
